Analogs of the pancreatic peptide hormone amylin are making strides in obesity as developers zoom in on oral drugs that can emulate or even improve on injectable GLP-1 agonists while avoiding muscle loss and gastrointestinal troubles. Access options Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription 27,99 € / 30 days cancel...
FlashNews:
The Only Shelby Built From The Ground-Up Ditched Ford For An Oldsmobile V8
These Types Of Tires Have The Worst Warranty
The moon might be more prone to fires
Gemini can now see your Google Photos — and generate
5 Subscription Services That Are Actually Worth The Money, According To Users
Apple could get a taste of sub-nanometer chips in 2029
‘That was a wonderful toilet’: Artemis 2 commander defends mission’s lunar loo
The Alarm Clock Consumer Reports Recommends For A Better Night’s Sleep
Building trust in the AI era with privacy-led UX
Blackmagic’s DaVinci Resolve 21 takes on Adobe Lightroom with a new Photo page
Two suspects have been arrested for allegedly shooting at Sam
Mozilla says Microsoft is using Copilot and Edge to tighten its grip on Windows
Excellence Is a Habit
This macOS bug is so rare, you’ll probably never experience it
Artemis 3 and beyond: What’s next for NASA after Artemis 2 moon success
My go-to electric screwdriver is on sale for over 50 percent off today
The Artemis II astronauts are back after a 10-day journey
Google Cloud deepens AI infrastructure partnership with Intel across Xeon and custom chips
iOS and iPadOS 26.4.1 is out to fix iCloud syncing bug
Home
drugs